©
OUI, Rob Law
The impact report sets out OUI’s support to form cutting edge spinouts and the return of millions of pounds to the University of Oxford to fund future innovation and research. The report was unveiled at an Oxford Innovation Society (OIS) event for academic founders and leaders, venture capital investors, industry and ecosystem partners.
According to OUI’s preliminary output metrics, between August (2023) and July (2024), OUI and their partners:
- Raised £19.5m in seed funding
- Raised £872m in investment for Oxford’s companies
- Created 15 new companies, including 10 spinouts, 2 social ventures, and 3 start-ups
- Filed 93 new patents
- Struck 1,239 licensing deals from health tech to clean energy.
Key achievements over the past 12 months include:
- The launch of Oxford University spinout MatchBio in January 2024 with a £4.5m investment. The company is working to revolutionise immunotherapy to fight cancer, by enhancing T Cell-based therapies.
- A new licensing agreement between Oxford University and biopharmaceutical company Apollo Therapeutics to accelerate the commercialisation of Oxford’s biomedical research by developing new therapies at pace.
- The first deliveries of Oxford’s R21 / Matrix-M malaria vaccine in Africa, following a licensing deal OUI negotiated with the Serum Institute of India.
- The purchase of student-led start-up Onfido by global security company Entrust Corp in April 2024. This represents the largest ever student-led company return on investment for the University of Oxford. Onfido uses artificial intelligence to verify customer identities, as well as providing vital fraud detection signals. Over the past year, Onfido has helped prevent $3.9bn in fraud losses for its global client base.
- Samsung Electronics’ acquisition of Oxford Semantic Technologies, a spinout which specialised in cutting-edge knowledge graph and reasoning techno
Read the full story on the University of Oxford website.